Rational design and development of a multi-antigen, multi-peptide vaccine based on genomic information to prevent lung cancer initiation and PROGRESSIONHHSN2612015000371
Ended Awarded Last action
- Contract number
- HHSN26100004
- Awardee
-
The Medical College Of Wisconsin, Inc. UEI E8VWJXMMUQ67
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $629,116
Award facts
- Opportunity
-
- N01CN5500347 Solicitation number
- Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Sep 25, 2015
- Preclinical PREVENT Cancer Program for Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Jan 5, 2015
- Contract value 100% obligated
- $629,115.70 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Wauwatosa, WI 53226, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$1,644 | |
| Other Administrative Action | $0 | |
| Original award | $630,760 |
About this award
The Medical College of Wisconsin, Inc. was awarded a firm fixed price delivery order valued at six hundred twenty-nine thousand one hundred fifteen dollars and seventy cents ($629,115.70) by the National Cancer Institute, a component of the National Institutes of Health within the Department of Health and Human Services. The delivery order was issued against the PREVENT Cancer Program master indefinite-delivery/indefinite-quantity contract vehicle to support the PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS program. Specifically, the prime contractor will conduct rational design and development of a multi-antigen, multi-peptide vaccine based on genomic information to prevent lung cancer initiation and progression. Performance will occur in Milwaukee, Wisconsin over a three year period from May 2016 through May 2019.
Quick answers
Who was awarded contract HHSN26100004?
HHSN26100004 was awarded to The Medical College Of Wisconsin, Inc. by National Cancer Institute (National Institutes of Health) on May 9, 2016.
How much is contract HHSN26100004 worth?
The government has obligated $629,116 on HHSN26100004.
Is contract HHSN26100004 an order under another contract?
Yes. HHSN26100004 is a delivery order under HHSN261201500037I, an indefinite delivery contract, on PREVENT Cancer Program (PREVENT).
Was contract HHSN26100004 competed?
The extent of competition for HHSN26100004 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award